Literature DB >> 11983177

The V(D)J recombinase efficiently cleaves and transposes signal joints.

Matthew B Neiditch1, Gregory S Lee, Leslie E Huye, Vicky L Brandt, David B Roth.   

Abstract

V(D)J recombination generates two types of products: coding joints, which constitute the rearranged variable regions of antigen receptor genes, and signal joints, which often form on immunologically irrelevant, excised circular molecules that are lost during cell division. It has been widely believed that signal joints simply convert reactive broken DNA ends into safe, inert products. Yet two curious in vivo observations made us question this assumption: signal ends are far more abundant than coding ends, and signal joints form only after RAG expression is downregulated. In fact, we find that signal joints are not at all inert; they are cleaved quite efficiently in vivo and in vitro by a nick-nick mechanism and form an excellent substrate for RAG-mediated transposition in vitro, possibly explaining how genomic stability in lymphocytes may be compromised.

Mesh:

Substances:

Year:  2002        PMID: 11983177     DOI: 10.1016/s1097-2765(02)00494-x

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  15 in total

1.  Regulation of RAG1/RAG2-mediated transposition by GTP and the C-terminal region of RAG2.

Authors:  Chia-Lun Tsai; David G Schatz
Journal:  EMBO J       Date:  2003-04-15       Impact factor: 11.598

2.  Mobilization of RAG-generated signal ends by transposition and insertion in vivo.

Authors:  Monalisa Chatterji; Chia-Lun Tsai; David G Schatz
Journal:  Mol Cell Biol       Date:  2006-02       Impact factor: 4.272

3.  In vivo transposition mediated by V(D)J recombinase in human T lymphocytes.

Authors:  Terri L Messier; J Patrick O'Neill; Sai-Mei Hou; Janice A Nicklas; Barry A Finette
Journal:  EMBO J       Date:  2003-03-17       Impact factor: 11.598

Review 4.  V(D)J recombination: Born to be wild.

Authors:  Dale A Ramsden; Brett D Weed; Yeturu V R Reddy
Journal:  Semin Cancer Biol       Date:  2010-07-01       Impact factor: 15.707

5.  Ataxia telangiectasia mutated (Atm) and DNA-PKcs kinases have overlapping activities during chromosomal signal joint formation.

Authors:  Eric J Gapud; Yair Dorsett; Bu Yin; Elsa Callen; Andrea Bredemeyer; Grace K Mahowald; Kazuo Q Omi; Laura M Walker; Jeffrey J Bednarski; Peter J McKinnon; Craig H Bassing; Andre Nussenzweig; Barry P Sleckman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-18       Impact factor: 11.205

6.  The T-cell receptor beta variable gene promoter is required for efficient V beta rearrangement but not allelic exclusion.

Authors:  Chun Jeih Ryu; Brian B Haines; Hye Ran Lee; Yun Hee Kang; Dobrin D Draganov; Minhui Lee; Charles E Whitehurst; Hyo Jeong Hong; Jianzhu Chen
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

7.  Violations of the 12/23 rule at the mouse immunoglobulin kappa locus, including V kappa-V kappa rearrangement.

Authors:  Jeffrey M Vinocur; Andrew D Fesnak; Yang Liu; Deepshikha Charan; Eline T Luning Prak
Journal:  Mol Immunol       Date:  2009-05-20       Impact factor: 4.407

8.  In vivo reinsertion of excised episomes by the V(D)J recombinase: a potential threat to genomic stability.

Authors:  Katrina Vanura; Bertrand Montpellier; Trang Le; Salvatore Spicuglia; Jean-Marc Navarro; Olivier Cabaud; Sandrine Roulland; Elodie Vachez; Immo Prinz; Pierre Ferrier; Rodrig Marculescu; Ulrich Jäger; Bertrand Nadel
Journal:  PLoS Biol       Date:  2007-03       Impact factor: 8.029

9.  Transpositionally active episomal hAT elements.

Authors:  David A O'Brochta; Christina D Stosic; Kristina Pilitt; Ramanand A Subramanian; Robert H Hice; Peter W Atkinson
Journal:  BMC Mol Biol       Date:  2009-12-14       Impact factor: 2.946

10.  Chromosomal reinsertion of broken RSS ends during T cell development.

Authors:  John D Curry; Danae Schulz; Cynthia J Guidos; Jayne S Danska; Lauryl Nutter; Andre Nussenzweig; Mark S Schlissel
Journal:  J Exp Med       Date:  2007-09-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.